IP Library Granted Patent US 10,722,502
Granted Patent B2
US 10,722,502 · App. 16/163,942 · Granted Jul 28, 2020

Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Inventors: Zhe Li (San Diego, CA); Stephan D. Parent (South San Francisco, CA); Travis Houston (South San Francisco, CA)
Assignee: Global Blood Therapeutics, Inc.
A61K31/4439A61P1/04A61P11/00A61P25/28A61P35/00C07D401/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,722,502
App. No.
16/163,942
Granted
Jul 28, 2020
Kind
B2
Abstract

Disclosed are crystalline free base an solvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).

Claims (4)

1. A composition comprising a crystalline ansolvate of Compound 1:

characterized by X-ray powder diffraction peaks (Cu Kα radiation) at 13.37 ° , 14.37 ° , 19.95° and 23.92 °2 θ (each ±0.2 °2θ), wherein the composition is substantially free of other ansolvate polymorphs of Compound 1.

2. The composition of claim 1 , wherein the crystalline ansolvate of Compound 1 is characterized by an X-ray powder diffraction pattern (Cu Kα radiation) substantially similar to that of FIG. 5 .

3. The composition of claim 1 , wherein the crystalline ansolvate of Compound 1 is characterized by an endothermic peak at 97 ± 2 ° C. as measured by differential scanning calorimetry.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2022
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 061620/0186 →
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 22, 2021
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058575/0921 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 9, 2020
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054664/0871 →
SECURITY INTEREST Recorded Dec 20, 2019
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051396/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2019
From: LI, ZHE
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 049653/0837 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2019
From: AMRI SSCI, LLC
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 049653/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2019
From: PARENT, STEPHAN D.; HOUSTON, TRAVIS
To: AMRI SSCI, LLC
Reel/Frame 049653/0900 →
Continuity (6)
Continuation 15801152 · Nov 1, 2017
Continuation 15236283 · Aug 12, 2016
Continuation 14616548 · Feb 6, 2015
Provisional Application 61937393 · Feb 7, 2014
Provisional Application 61937404 · Feb 7, 2014
Related Publication 20190255031A1 · Aug 22, 2019